Hyperbaric oxygen therapy market seen doubling to $7.1 billion by 2035

The global hyperbaric oxygen therapy market is projected to rise from $3.75 billion in 2025 to $7.10 billion by 2035, driven by chronic wound care, broader clinical use and chamber technology upgrades. North America leads now, while Asia-Pacific is positioned for the fastest expansion as diabetes care and specialty treatment infrastructure grow.

Why it matters: - Hyperbaric oxygen therapy is moving from a niche treatment toward broader use in wound care and selected medical conditions. - The market’s projected growth signals rising demand for noninvasive therapies that can help manage chronic wounds, diabetic foot ulcers and radiation-related tissue injury. - Hospitals, wound-care centers and specialty clinics could expand treatment capacity as patient volumes and referral pathways increase.

What happened: - Market Research Future projects the global hyperbaric oxygen therapy market will grow from $3.50 billion in 2024 to $3.75 billion in 2025. - The market is forecast to reach $7.10 billion by 2035, based on a 6.80% compound annual growth rate from 2025 through 2035. - The forecast was released August 12, 2026. - The treatment uses elevated atmospheric pressure and high oxygen concentrations to increase oxygen delivery to tissues.

The details: - Chronic and difficult-to-heal wounds are a core demand driver. - Diabetic foot ulcers remain a major use case as diabetes prevalence rises worldwide. - Hyperbaric oxygen therapy is also used for radiation tissue damage, compromised grafts and flaps, decompression sickness, carbon monoxide poisoning and other selected indications. - Hospitals and wound-care centers are building multidisciplinary programs that combine hyperbaric therapy with debridement, infection control, vascular management and offloading. - Monoplace chambers remain the dominant product type because of their compact design and use for individual treatment sessions. - Multiplace chambers serve higher-volume facilities and allow several patients to be treated simultaneously under supervision. - Consumables include masks, hoods, monitoring accessories and other recurring supplies. - Wound healing is the leading application segment. - Hospitals are the dominant end user. - Wound-care centers are among the fastest-growing end users. - Portable chambers are an emerging category, though clinical use depends on safety and regulatory requirements. - North America holds a major share of the market, led by the United States. - Europe is a significant market, with Germany, the UK, France and Italy contributing demand. - Asia-Pacific offers the strongest growth potential, with China, India, Japan and South Korea increasing investment in advanced medical technologies. - South America is an emerging market, with Brazil singled out as an important country. - The Middle East and Africa remain an emerging opportunity as hospital infrastructure expands.

Between the lines: - The market is being pulled by two trends at once: more patients with chronic wounds and more confidence in established hyperbaric indications. - Equipment makers are competing on safety, patient comfort, monitoring technology, energy efficiency and installation flexibility. - Better digital monitoring and connected chamber systems could make treatment delivery more efficient and improve quality control. - Reimbursement, specialist availability and equipment cost remain important barriers in several regions.

What's next: - Hospitals and specialty centers are likely to keep integrating hyperbaric treatment into broader wound-care pathways through 2035. - Manufacturers are expected to focus on quieter chambers, improved communication systems, easier monitoring and stronger safety features. - Expansion in Asia-Pacific, the Middle East and other developing markets could add new demand for cost-effective systems. - The market’s next phase depends on how quickly healthcare systems expand specialist wound-care services and adopt chamber upgrades.

The bottom line: - Hyperbaric oxygen therapy is on a steady growth path, supported by chronic wound demand, accepted clinical uses and improving chamber technology.